TransCode Therapeutics and Quantum Leap Collaborate on Phase 2a Trial for Colorectal Cancer Treatment
TL;DR
TransCode Therapeutics gains a strategic advantage by testing TTX-MC138 in the PRE-I-SPY trial, potentially positioning its RNA therapy as a leading precision treatment for colorectal cancer recurrence.
TransCode's TTX-MC138 will be evaluated in a Phase 2a trial starting in 2026, targeting ctDNA-positive colorectal cancer patients to assess biological activity in minimal residual disease.
This collaboration aims to develop better treatments for colorectal cancer patients at high risk of recurrence, potentially improving survival and quality of life through precision medicine.
TransCode is pioneering an RNA therapy targeting a specific metastasis biomarker, exploring a novel approach to treat cancer that has spread at the microscopic level.
Found this article helpful?
Share it with your network and spread the knowledge!
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) and Quantum Leap Healthcare Collaborative have announced a collaboration to evaluate TransCode's lead therapeutic candidate, TTX-MC138, in the PRE-I-SPY Phase 2a clinical trial platform. The trial plans to enroll up to 45 colorectal cancer patients who are ctDNA positive following standard curative-intent therapy, beginning in the first half of 2026.
The study will be led by Dr. Paula Pohlmann of MD Anderson Cancer Center and will assess the biological and clinical activity of TTX-MC138 in the minimal residual disease setting. This setting represents a critical phase in cancer treatment where recurrence risk is high and therapeutic options are limited, reflecting growing interest in precision treatments targeting micrometastatic disease.
TransCode Therapeutics is a clinical-stage company pioneering immunoncology and RNA therapeutic treatments for high-risk and advanced cancers. The company's lead candidate, TTX-MC138, focuses on treating metastatic tumors that overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. The collaboration with Quantum Leap represents a significant step in advancing this therapeutic approach for colorectal cancer patients who face high recurrence rates despite initial treatment success.
The importance of this trial lies in addressing a substantial unmet medical need. Patients with minimal residual disease following standard therapy have limited treatment options and face significant recurrence risks. By targeting micrometastatic disease through precision medicine approaches, this collaboration could potentially change the treatment paradigm for colorectal cancer survivors. The trial's focus on ctDNA-positive patients allows for more targeted patient selection, potentially increasing the likelihood of demonstrating clinical benefit.
For the broader oncology field, this collaboration represents the growing trend toward personalized medicine and targeted therapies for cancer recurrence prevention. The PRE-I-SPY trial platform, known for its adaptive design and biomarker-driven approach, provides an ideal framework for evaluating novel therapies like TTX-MC138. Success in this trial could validate the approach of targeting microRNA-10b as a strategy for preventing cancer metastasis and recurrence.
The latest news and updates relating to RNAZ are available in the company's newsroom at https://ibn.fm/RNAZ. For more information about InvestorWire, the specialized communications platform that distributed this announcement, please visit https://www.InvestorWire.com. Full terms of use and disclaimers applicable to all content provided by InvestorWire are available at https://www.InvestorWire.com/Disclaimer.
Curated from InvestorBrandNetwork (IBN)
